Gaurav Mehta

2.1k citations
36 papers · 1.3k indexed · h-index 21
Topics
Complement system in diseases (8 papers)Monoclonal and Polyclonal Antibodies Research (6 papers)Chromatin Remodeling and Cancer (5 papers)

In The Last Decade

Gaurav Mehta

35 papers receiving 1.3k citations

Peers

Gaurav Mehta
Comparison fields: 5 of 105
  • Molecular Biology 526
  • Immunology 361
  • Oncology 263
  • Cancer Research 203
  • Radiology, Nuclear Medicine and Imaging 150
Replace Myriam Fabre with:
Myriam Fabre Spain
Kary A. Latham United States
Sue‐Yun Hwang South Korea
Gautam Adhikary United States
Leihong Xiang China
Michaël Devos Belgium
Takeshi Hara Japan
Ruy Tchao United States
Tianwen Gao China
Judith Agudo United States
Gaurav Mehta relative to Myriam Fabre Spain Myriam Fabre's profile →
Citations per field
00.5×4.8×
Myriam Fabre · 1×
Citations per year

Countries citing papers authored by Gaurav Mehta

Since Specialization
Citations

This map shows the geographic impact of Gaurav Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gaurav Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gaurav Mehta more than expected).

Fields of papers citing papers by Gaurav Mehta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gaurav Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gaurav Mehta. The network helps show where Gaurav Mehta may publish in the future.

Co-authorship network of co-authors of Gaurav Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Gaurav Mehta. A scholar is included among the top collaborators of Gaurav Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gaurav Mehta. Gaurav Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 14
2 0
3 7
4 19
5 30
6 209
7 21
8 130
9 41
10 19
11 21
12 32
13 21
14 78
15 16
16 29
17 11
18 33
19 148
20 71

About Gaurav Mehta

Gaurav Mehta is a scholar working on Immunology and Allergy, Hematology and Immunology, having authored 36 papers that have together received 1.3k indexed citations. Recurring topics across this work include Complement system in diseases (8 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Chromatin Remodeling and Cancer (5 papers). The work is most often cited by research in Immunology (361 citations), Cancer Research (203 citations) and Pharmaceutical Science (68 citations). Gaurav Mehta has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Vasilis Vasiliou, Ying Chen, Nirmal K. Banda, Michael L. Gatza, V. Michael Holers, Charles M. Perou, Katherine A. Hoadley, Pooja Khanna, Robert I. Scheinman and Naveen Ahuja. Their work appears in journals such as Nucleic Acids Research, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026